Previous efforts to circumvent the problem of the size limitation imposed by the AAV vector have focused mainly on altering the candidate genes into ‘mini-expression cassettes’ suitable for ...

In neuromuscular diseases, the most widely used vector for transporting genetic material is the natural adeno-associated virus (AAV). However, a large proportion of injected vectors do not reach ...

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

Privately held Dyno Therapeutics Inc. has added another notch to its adeno-associated virus (AAV) vectors development ...

Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm’s clinical program is a LVV-based gene therapy for ...

Experts discussed trends in clinical trial operations at the recent Outsourcing in Clinical Trials and Clinical Trials Supply ...

alleges the university and Wilson engaged in "unethical and illegal conduct" in their licensing of technology she invented covering AAV vector used to deliver gene therapies. The lawsuit states ...

Similarly, GoQURE incorporates gene silencing with gene replacement within one AAV vector. This approach removes the mutated gene's toxic products while repairing function by replacing the faulty ...

Existing gene therapies have primarily used a small number of naturally occurring AAV vectors limited by low delivery efficiency as well as problems with pre-existing immunity and manufacturability.

Explore the role and challenges of AAV characterization, the significance of capsid filling, and the best methods to enhance gene therapy.

Adeno-associated viral vectors (AAV) have emerged as key players in this growth trajectory, projected to capture a ...

In the GAN trial, participants who were baseline AAV9 seropositive showed higher anti-AAV9 neutralizing antibody titers in the serum and experienced faster vector clearance after CSF-AAV ...